These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28511997)

  • 1. Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm.
    Wiśniowska B; Tylutki Z; Polak S
    Drug Discov Today; 2017 Oct; 22(10):1460-1465. PubMed ID: 28511997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
    Patel N; Wisniowska B; Polak S
    AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT Assessment in Early Drug Development: The Long and the Short of It.
    Lester RM; Paglialunga S; Johnson IA
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
    J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT prolongation is an unreliable predictor of ventricular arrhythmia.
    Hondeghem LM
    Heart Rhythm; 2008 Aug; 5(8):1210-2. PubMed ID: 18675236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
    Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
    Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of baseline measurement on the change from baseline in QTc intervals.
    Tian H; Natarajan J
    J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of cardiac safety translational tools for QT prolongation and torsade de pointes.
    Valerio LG; Balakrishnan S; Fiszman ML; Kozeli D; Li M; Moghaddam S; Sadrieh N
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):801-15. PubMed ID: 23537164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enabling robust assessment of QTc prolongation in early phase clinical trials.
    Mehrotra DV; Fan L; Liu F; Tsai K
    Pharm Stat; 2017 May; 16(3):218-227. PubMed ID: 28374497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia Risk.
    Johannesen L; Vicente J; Hosseini M; Strauss DG
    PLoS One; 2016; 11(12):e0166925. PubMed ID: 28036330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.
    Shah RR; Morganroth J
    Drug Saf; 2012 Sep; 35(9):695-709. PubMed ID: 22845313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.